과제정보
This work was supported by grants (NRF-2018R1C1B5041536, 2018R1A5A2024181) from the National Research Foundation of Korea (NRF), funded by the Korea government (MSIT)
참고문헌
- Sirohi B, Powles R. Multiple myeloma. Lancet 2004;363:875-887. https://doi.org/10.1016/S0140-6736(04)15736-X
- Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-1873. https://doi.org/10.1056/NEJMra041875
- Hong J, Lee JH. Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med 2016;31:820-834. https://doi.org/10.3904/kjim.2015.408
- Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol 2009;145:681-708. https://doi.org/10.1111/j.1365-2141.2009.07649.x
- Attal M, Harousseau JL. The role of high-dose therapy with autologous stem cell support in the era of novel agents. Semin Hematol 2009;46:127-132. https://doi.org/10.1053/j.seminhematol.2009.02.006
- Dosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies. Blood Cancer J 2015;5:e306. https://doi.org/10.1038/bcj.2015.32
- Leung W. Immunotherapy in acute leukemia. Semin Hematol 2009;46:89-99. https://doi.org/10.1053/j.seminhematol.2008.09.004
- Guillerey C, Nakamura K, Vuckovic S, Hill GR, Smyth MJ. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci 2016;73:1569-1589. https://doi.org/10.1007/s00018-016-2135-z
- Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell 2017;168:724-740. https://doi.org/10.1016/j.cell.2017.01.016
- Bensinger W, Rotta M, Storer B, et al. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant 2012;47:1312-1317. https://doi.org/10.1038/bmt.2012.1
- Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22-32. https://doi.org/10.1038/leu.2009.236
- Vo MC, Nguyen-Pham TN, Lee HJ, et al. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model. Oncotarget 2017;8:27252-27262. https://doi.org/10.18632/oncotarget.15917
- Vo MC, Nguyen-Pham TN, Lee HJ, et al. Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells. Oncotarget 2017;8:46047-46056. https://doi.org/10.18632/oncotarget.17517
- Al-Hujaily EM, Oldham RA, Hari P, Medin JA. Development of novel immunotherapies for multiple myeloma. Int J Mol Sci 2016;17:E1506.
- Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? Blood 2017;129:275-279. https://doi.org/10.1182/blood-2016-08-731885
- Jung SH, Lee HJ, Vo MC, Kim HJ, Lee JJ. Immunotherapy for the treatment of multiple myeloma. Crit Rev Oncol Hematol 2017;111:87-93. https://doi.org/10.1016/j.critrevonc.2017.01.011
- Kim YS, Park HJ, Park JH, et al. A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells. Oncoimmunology 2018;7:e1472187. https://doi.org/10.1080/2162402X.2018.1472187
- Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002;100:230-237. https://doi.org/10.1182/blood.V100.1.230
- Vo MC, Anh-NguyenThi T, Lee HJ, et al. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. Exp Hematol 2017;46:48-55. https://doi.org/10.1016/j.exphem.2016.11.004
- Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621-627. https://doi.org/10.1016/S1083-8791(00)70027-9
- Jung SH, Lee YK, Lee HJ, et al. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro. Exp Hematol 2014;42:274-281. https://doi.org/10.1016/j.exphem.2013.12.008
- Choi NR, Lee HJ, Jung SH, et al. Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca(2+) transport ATPase 2 regulation. Cytotherapy 2015;17:1421-1433. https://doi.org/10.1016/j.jcyt.2015.06.002
- Hoang MD, Jung SH, Lee HJ, et al. Dendritic cell-based cancer immunotherapy against multiple myeloma: from bench to clinic. Chonnam Med J 2015;51:1-7. https://doi.org/10.4068/cmj.2015.51.1.1
- Hoang MD, Lee HJ, Lee HJ, et al. Branched polyethylenimine-superparamagnetic iron oxide nanoparticles (bPEI-SPIONs) improve the immunogenicity of tumor antigens and enhance Th1 polarization of dendritic cells. J Immunol Res 2015;2015:706379.
- Hong CY, Lee HJ, Choi NR, et al. Sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells. Exp Mol Med 2016;48:e253. https://doi.org/10.1038/emm.2016.69
- Lee HJ, Choi NR, Vo MC, Hoang MD, Lee YK, Lee JJ. Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine. Methods Mol Biol 2014;1139:17-26. https://doi.org/10.1007/978-1-4939-0345-0_2
- Vo MC, Lee HJ, Kim JS, et al. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity. Oncotarget 2015;6:33781-33790. https://doi.org/10.18632/oncotarget.5281
- Jung SH, Lee HJ, Lee YK, et al. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. Oncotarget 2017;8:41538-41548. https://doi.org/10.18632/oncotarget.14582
- Neuber B, Herth I, Tolliver C, et al. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J Immunol 2011;187:1047-1056. https://doi.org/10.4049/jimmunol.1002460
- Nguyen-Pham TN, Jung SH, Vo MC, et al. Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma. J Immunother 2015;38:330-339. https://doi.org/10.1097/CJI.0000000000000097
- Vo MC, Yang S, Jung SH, et al. Synergistic antimyeloma activity of dendritic cells and pomalidomide in a murine myeloma model. Front Immunol 2018;9:1798. https://doi.org/10.3389/fimmu.2018.01798
- Rosenblatt J, Glotzbecker B, Mills H, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011;34:409-418. https://doi.org/10.1097/CJI.0b013e31821ca6ce
- Vo MC, Jung SH, Chu TH, et al. Lenalidomide and programmed death-1 blockade synergistically enhances the effects of dendritic cell vaccination in a model of murine myeloma. Front Immunol 2018;9:1370. https://doi.org/10.3389/fimmu.2018.01370
- Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013;10:267-276. https://doi.org/10.1038/nrclinonc.2013.46
- Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest 2016;126:2588-2596. https://doi.org/10.1172/JCI86000
- Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 2015;125:4017-4023. https://doi.org/10.1182/blood-2014-12-580068
- Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388-398. https://doi.org/10.1158/2159-8290.CD-12-0548
- Zhao Z, Condomines M, van der Stegen SJC, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 2015;28:415-428. https://doi.org/10.1016/j.ccell.2015.09.004
- First-ever CAR T-cell therapy approved in U.S. Cancer Discov 2017;7:OF1.
- Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood 2017;130:2594-2602. https://doi.org/10.1182/blood-2017-06-793869
- Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82. https://doi.org/10.1083/jcb.124.1.71
- Kawamura T, Ogawa Y, Shimozato O, et al. CD70 is selectively expressed on Th1 but not on Th2 cells and is required for Th1-type immune responses. J Invest Dermatol 2011;131:1252-1261. https://doi.org/10.1038/jid.2011.36
- Van Acker HH, Capsomidis A, Smits EL, Van Tendeloo VF. CD56 in the immune system: more than a marker for cytotoxicity? Front Immunol 2017;8:892. https://doi.org/10.3389/fimmu.2017.00892
- Drent E, Themeli M, Poels R, et al. A rational strategy for reducing on-target off-tumor effects of cd38-chimeric antigen receptors by affinity optimization. Mol Ther 2017;25:1946-1958. https://doi.org/10.1016/j.ymthe.2017.04.024
- Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993;81:2658-2663. https://doi.org/10.1182/blood.V81.10.2658.2658
- Podar K, Anderson KC. The evolution and maintenance of the multiple myeloma cell clone within the liquid bone marrow compartment: therapeutic implications. In: Bradshaw RA, Dennis EA, eds. Handbook of Cell Signaling (Second Edition). Burlington (VT): Academic Press, 2010:2799-2809.
- Guo B, Chen M, Han Q, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother 2016;2:28-35. https://doi.org/10.1016/j.jocit.2014.11.001
- Garfall AL, Stadtmauer EA, Hwang WT, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 2018;3:e120505. https://doi.org/10.1172/jci.insight.120505
- Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68:190-197. https://doi.org/10.1158/0008-5472.CAN-07-3096
- Raje NS, Berdeja JG, Lin Y, et al. bb2121 Anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: updated results from a multicenter phase I study. J Clin Oncol 2018;36(15 Suppl):8007. https://doi.org/10.1200/JCO.2018.36.15_suppl.8007
- Cohen AD, Garfall AL, Stadtmauer EA, et al. Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood 2017;130(Suppl 1):505.
- Smith EL, Staehr M, Masakayan R, et al. Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Mol Ther 2018;26:1447-1456. https://doi.org/10.1016/j.ymthe.2018.03.016
- Fan F, Zhao W, Liu J, et al. Durable remissions with BC-MA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. J Clin Oncol 2017;35(18 Suppl):LBA3001. https://doi.org/10.1200/JCO.2017.35.18_suppl.LBA3001
- Yan L, Shang J, Kang L, et al. Combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for RRMM: initial safety and efficacy report from a clinical pilot study. Blood 2017;130(Suppl 1):506.
- Ping Y, Liu C, Zhang Y. T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein Cell 2018;9:254-266. https://doi.org/10.1007/s13238-016-0367-1
- Kunert A, Straetemans T, Govers C, et al. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu. Front Immunol 2013;4:363.
- Debets R, Donnadieu E, Chouaib S, Coukos G. TCR-engineered T cells to treat tumors: seeing but not touching? Semin Immunol 2016;28:10-21. https://doi.org/10.1016/j.smim.2016.03.002
- Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2015;21:914-921. https://doi.org/10.1038/nm.3910
- Malhotra A, Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy 2011;3:1143-1166. https://doi.org/10.2217/imt.11.102
- Rezvani K, Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 2015;6:578.
- Marcus A, Gowen BG, Thompson TW, et al. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 2014;122:91-128. https://doi.org/10.1016/B978-0-12-800267-4.00003-1
- Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma. Int J Hematol 2018;107:278-285. https://doi.org/10.1007/s12185-018-2405-7
- Frohn C, Hoppner M, Schlenke P, Kirchner H, Koritke P, Luhm J. Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 2002;119:660-664. https://doi.org/10.1046/j.1365-2141.2002.03879.x
- Garg TK, Szmania SM, Khan JA, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica 2012;97:1348-1356. https://doi.org/10.3324/haematol.2011.056747
- Shah N, Martin-Antonio B, Yang H, et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013;8:e76781. https://doi.org/10.1371/journal.pone.0076781
- Szmania S, Lapteva N, Garg T, et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother 2015;38:24-36. https://doi.org/10.1097/CJI.0000000000000059
- Shah N, Li L, McCarty J, et al. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 2017;177:457-466. https://doi.org/10.1111/bjh.14570
- Leivas A, Perez-Martinez A, Blanchard MJ, et al. Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. Oncoimmunology 2016;5:e1250051. https://doi.org/10.1080/2162402X.2016.1250051
- Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014;28:917-927. https://doi.org/10.1038/leu.2013.279
- Liu D, Tian S, Zhang K, et al. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. Protein Cell 2017;8:861-877. https://doi.org/10.1007/s13238-017-0415-5
- Glienke W, Esser R, Priesner C, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol 2015;6:21.
- von Strandmann EP, Hansen HP, Reiners KS, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006;107:1955-1962. https://doi.org/10.1182/blood-2005-05-2177
피인용 문헌
- Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma vol.20, pp.5, 2019, https://doi.org/10.1021/acs.jproteome.1c00007